Community-directed treatment activities are funded through three mechanisms:
- trust funds available through APOC
- contributions from the national governments of APOC countries
- funds from non-governmental development organizations.
APOC Trust Fund
APOC is funded entirely from voluntary contributions. The World Bank is the fiscal agent of APOC. It manages the APOC Trust Fund and reports annually to the Joint Action Forum on the financial situation of APOC.
Summary of APOC Trust Fund resources
|Approved budget (1996–2010)||US$ 135 million|
|Funds pledged (1996–2010)||US$ 128 million|
|Expenditures (1996–2007)||US$ 112.5 million|
|Funds pledged but not spent (1996–2010)||US$ 15.5 million|
|Funding gap (1996–2010)||US$ 7.0 million|
|Additional funds required to extend activities to 2015:||US$ 46.4 million|
|Total funding gap (1996–2015)||US$ 53.4 million|
|Total resources (1996–2015)||US$ 181.4 million|
To extend APOC activities to 2015, US$ 60 million was raised during the meeting of the Joint Action Forum in Brussels in December 2007.
At the same meeting, and in celebration of the 20th anniversary of the donation of Mectizan® (ivermectin), the manufacturer of the drug – Merck & Co., Inc. – also joined as a financial donor of APOC.
How is the money spent?
Over 80% of funds are spent on technical and operational activities in endemic countries. The graph shows how spending will decrease from 2008 to 2015 (blue bars), when APOC’s mandate will end. By this time, it is planned that funding for sustained community-directed treatment in countries will be provided by the governments and non-governmental development organizations.
Annual Trust Fund expenditure
The table shows the breakdown of the 2008–2015 budget by objective.
Projected Trust Fund expenditure for technical and operational activities (2008–2015)
|Objective 1: To establish sustainable national onchocerciasis programmes in all endemic African countries.||24.78|
|Objective 2: To co-implement onchocerciasis control activities with other interventions (such as vitamin A supplements and anti-worm medicines).||5.21|
|Objective 3: To determine when and where to stop ivermectin treatment.||9.96|
|Objective 4: To reduce the risk of transmission of onchocerciasis from ex-OCP (Onchocerciasis Control Programme in West Africa) countries.||5.4|
|Objective 5: To ensure that governments ultimately take full responsibility for onchocerciasis control.||0.84|
|Objective 6: To cease all APOC operations without jeopardizing past achievements and investments.||6.89|
Donor countries, institutions and foundations
- African Development Bank
- Calouste Gulbenkian Foundation
- Merck & Co., Inc.
- The Netherlands
- OPEC Fund
- Saudi Arabia
- United Kingdom of Great Britain and Northern Ireland
- United States of America
- World Bank
- World Health Organization